UY36209A - Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen - Google Patents
Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienenInfo
- Publication number
- UY36209A UY36209A UY0001036209A UY36209A UY36209A UY 36209 A UY36209 A UY 36209A UY 0001036209 A UY0001036209 A UY 0001036209A UY 36209 A UY36209 A UY 36209A UY 36209 A UY36209 A UY 36209A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirazine
- agonists
- modulating
- derivatives
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen compuestos, composiciones y métodos para tratar trastornos que se afectan por la modulación del receptor GPR40. Tales compuestos se representan por la Fórmula (I) a continuación:en donde R1, G, y R2 se definen en la presente descripción.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462022257P | 2014-07-09 | 2014-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36209A true UY36209A (es) | 2016-01-29 |
Family
ID=53761519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036209A UY36209A (es) | 2014-07-09 | 2015-07-09 | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen |
Country Status (5)
Country | Link |
---|---|
US (1) | US9688642B2 (es) |
AR (1) | AR101132A1 (es) |
TW (1) | TW201613878A (es) |
UY (1) | UY36209A (es) |
WO (1) | WO2016007714A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019124A (ja) * | 2017-07-19 | 2019-02-07 | 日本化薬株式会社 | ピラジン化合物 |
WO2019099315A1 (en) * | 2017-11-16 | 2019-05-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TW202140440A (zh) * | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
JP2023528713A (ja) * | 2020-02-28 | 2023-07-06 | キャリーオペ,インク. | Gpr40アゴニスト |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2410391A1 (en) * | 2000-06-28 | 2002-11-28 | Ssp Co., Ltd. | Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts |
CA2891535A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
EP2925748B1 (en) * | 2012-11-28 | 2017-01-11 | Boehringer Ingelheim International GmbH | Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases |
-
2015
- 2015-07-07 TW TW104121962A patent/TW201613878A/zh unknown
- 2015-07-08 AR ARP150102181A patent/AR101132A1/es unknown
- 2015-07-09 WO PCT/US2015/039692 patent/WO2016007714A1/en active Application Filing
- 2015-07-09 US US14/794,907 patent/US9688642B2/en active Active
- 2015-07-09 UY UY0001036209A patent/UY36209A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20160009662A1 (en) | 2016-01-14 |
TW201613878A (en) | 2016-04-16 |
US9688642B2 (en) | 2017-06-27 |
AR101132A1 (es) | 2016-11-23 |
WO2016007714A1 (en) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
CO2017004074A2 (es) | Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
UY37537A (es) | Derivados de pirazol como inhibidores malt1 | |
NI201800075A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos. | |
CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
BR112017012272A2 (pt) | derivados de 2-anilinopirimidina como moduladores de egfr | |
BR112016014020A2 (pt) | Compostos moduladores de tetra-hidropiridopirazinas de gpr6, seus sais e os usos dos mesmos | |
CL2015002125A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
UY35469A (es) | Moduladores de p2x7 | |
CL2018003265A1 (es) | Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
PE20151793A1 (es) | Compuestos heterociclicos moduladores de la piruvato quinasa y composiciones que los contienen | |
UY37610A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
ECSP19055169A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
CL2018000696A1 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue. | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
ECSP19055179A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
CL2015002222A1 (es) | Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos. | |
CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
CL2016002515A1 (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1. |